Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications

European Journal of Immunology

Volumn 42, Issue 9, 2012, Pages 2232-2237

  Huh, Jun R ^a   Littman, Dan R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune diseases; ROR t; Th17 cells

Indexed keywords

DIGOXIN; INTERLEUKIN 17; LIVER X RECEPTOR; ML 209; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; NUCLEAR PROTEIN; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PROTEIN INHIBITOR; RETINOIC ACID RECEPTOR RELATED ORPHAN NUCLEAR RECEPTOR GAMMA T; SR 1001; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; URSOLIC ACID;

ARTHRITIS; CELL DIFFERENTIATION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GENE TARGETING; HUMAN; LIGAND BINDING; MOLECULAR LIBRARY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SHORT SURVEY; TH17 CELL; TRANSCRIPTION INITIATION;

ANIMALS; HUMANS; INTERLEUKIN-17; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; T-LYMPHOCYTES, HELPER-INDUCER; TH17 CELLS;

EID: 84865772592     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242740     Document Type: Short Survey

References (42)

1. Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A. et al., Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011. 71: 1263-1271.
2. Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J. et al., The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006. 126: 1121-1133.
3. Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie, B., Kleinschek, M. et al., IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 2006. 116: 1310-1316.
4. Serody, J. S. and Hill, G. R., The IL-17 differentiation pathway and its role in transplant outcome. Biol. Blood Marrow Transplant. 2012. 18: S56-S61.
5. Leppkes, M., Becker, C., Ivanov, II, Hirth, S., Wirtz, S., Neufert, C., Pouly, S. et al., RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009. 136: 257-267.
6. Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H. et al., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006. 314: 1461-1463.
7. Nair, R. P., Duffin, K. C., Helms, C., Ding, J., Stuart, P. E., Goldgar, D., Gudjonsson, J. E. et al., Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 2009. 41: 199-204.
8. Stahl, E. A., Raychaudhuri, S., Remmers, E. F., Xie, G., Eyre, S., Thomson, B. P., Li, Y. et al., Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 2010. 42: 508-514.
9. Spits, H. and Di Santo, J. P., The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 2011. 12: 21-27.
10. Lochner, M., Peduto, L., Cherrier, M., Sawa, S., Langa, F., Varona, R., Riethmacher, D. et al., In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J. Exp. Med. 2008. 205: 1381-1393.
11. Schraml, B. U., Hildner, K., Ise, W., Lee, W.-L., Smith, W. A.-E., Solomon, B., Sahota, G. et al., The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature 2009. 460: 405-409.
12. Zhou, L., Ivanov, I. I., Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D. E. et al., IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007. 8: 967-974.
13. Chung, Y., Chang, S., Martinez, G., Yang, X., Nurieva, R., Kang, H., Ma, L. et al., Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009. 30: 576-587.
14. Zhang, F., Meng, G. and Strober, W., Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat. Immunol. 2008. 9: 1297-1306.
15. Okamoto, K., Iwai, Y., Oh-Hora, M., Yamamoto, M., Morio, T., Aoki, K., Ohya, K. et al., IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. Nature 2010. 464: 1381-1385.
16. Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J. and Stockinger, B., The aryl hydrocarbon receptor links T(H)17-cell-mediated autoimmunity to environmental toxins. Nature 2008. 453: 106-109.
17. Qiu, J., Heller, J. J., Guo, X., Chen, Z. M., Fish, K., Fu, Y. X. and Zhou, L., The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 2012. 36: 92-104.
18. Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L. et al., T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008. 28: 29-39.
19. Dussault, I., Fawcett, D., Matthyssen, A., Bader, J. A. and Giguere, V., Orphan nuclear receptor ROR alpha-deficient mice display the cerebellar defects of staggerer. Mech. Dev. 1998. 70: 147-153.
20. Eberl, G., Marmon, S., Sunshine, M.-J., Rennert, P. D., Choi, Y. and Littman, D. R., An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 2004. 5: 64-73.
21. Yang, X., Downes, M., Yu, R. T., Bookout, A. L., He, W., Straume, M., Mangelsdorf, D. J. et al., Nuclear receptor expression links the circadian clock to metabolism. Cell 2006. 126: 801-810.
22. Kang, H. S., Angers, M., Beak, J. Y., Wu, X., Gimble, J. M., Wada, T., Xie, W. et al., Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Phys. Gen. 2007. 31: 281-294.
23. Huh, J. R., Leung, M. W., Huang, P., Ryan, D. A., Krout, M. R., Malapaka, R. R., Chow, J. et al., Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 2011. 472: 486-490.
24. Fujita-Sato, S., Ito, S., Isobe, T., Ohyama, T., Wakabayashi, K., Morishita, K., Ando, O. et al., Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. J. Biol. Chem. 2011. 286: 31409-31417.
25. Solt, L. A., Kumar, N., Nuhant, P., Wang, Y., Lauer, J. L., Liu, J., Istrate, M. A. et al., Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011. 472: 491-494.
26. Kumar, N., Lyda, B., Chang, M. R., Lauer, J. L., Solt, L. A., Burris, T. P., Kamenecka, T. M. et al., Identification of SR2211: a potent synthetic RORgamma-selective modulator. ACS Chem. Biol. 2012. 7: 672-677.
27. Xu, T., Wang, X., Zhong, B., Nurieva, R. I., Ding, S. and Dong, C., Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein. J. Biol. Chem. 2011. 286: 22707-22710.
28. Kojima, H., Muromoto, R., Takahashi, M., Takeuchi, S., Takeda, Y., Jetten, A. M. and Matsuda, T., Inhibitory effects of azole-type fungicides on interleukin-17 gene expression via retinoic acid receptor-related orphan receptors alpha and gamma. Toxicol. Appl. Pharmacol. 2012. 259: 338-345.
29. Cascao, R., Vidal, B., Raquel, H., Neves-Costa, A., Figueiredo, N., Gupta, V., Fonseca, J. E. et al., Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun. Rev. 2012. doi:10.1016/j.autrev.2012.02.022.
30. Jin, L., Martynowski, D., Zheng, S., Wada, T., Xie, W. and Li, Y., Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma. Mol. Endocrinol. 2010. 24: 923-929.
31. Manel, N., Unutmaz, D. and Littman, D. R., The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 2008. 9: 641-649.
32. Price, E. M. and Lingrel, J. B., Structure-function relationships in the Na, K-ATPase alpha subunit: site-directed mutagenesis of glutamine-111 to arginine and asparagine-122 to aspartic acid generates a ouabain-resistant enzyme. Biochemistry 1988. 27: 8400-8408.
33. Shaikh, I. M., Lau, B. W., Siegfried, B. A. and Valdes, R., Jr., Isolation of digoxin-like immunoreactive factors from mammalian adrenal cortex. J. Biol. Chem. 1991. 266: 13672-13678.
34. Doris, P. A. and Stocco, D. M., An endogenous digitalis-like factor derived from the adrenal gland: studies of adrenal tissue from various sources. Endocrinology 1989. 125: 2573-2579.
35. Robertson, L. W., Chandrasekaran, A., Reuning, R. H., Hui, J. and Rawal, B. D., Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum. Appl. Environ. Microbiol. 1986. 51: 1300-1303.
36. Saha, J. R., Butler, V. P., Jr., Neu, H. C. and Lindenbaum, J., Digoxin-inactivating bacteria: identification in human gut flora. Science 1983. 220: 325-327.
37. Bagrov, A. Y. and Shapiro, J. I., Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat. Clin. Pract. Nephrol. 2008. 4: 378-392.
38. Nesher, M., Shpolansky, U., Rosen, H. and Lichtstein, D., The digitalis-like steroid hormones: new mechanisms of action and biological significance. Life Sci. 2007. 80: 2093-2107.
39. Hooper, L. V., Littman, D. R. and Macpherson, A. J., Interactions Between the microbiota and the immune system. Science 2012. 336: 1268-1273.
40. Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C. et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008. 371: 1675-1684.
41. Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S. et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008. 371: 1665-1674.
42. Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D. et al., Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012. 366: 1190-1199.